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Abstract: Tetraspanins are suggested to regulate the composition of cell membrane components
and control intracellular transport, which leaves them vulnerable to utilization by pathogens such
as human papillomaviruses (HPV) and cytomegaloviruses (HCMV) to facilitate host cell entry and
subsequent infection. In this study, by means of cellular depletion, the cluster of differentiation
(CD) tetraspanins CD9, CD63, and CD151 were found to reduce HPV16 infection in HeLa cells by
50 to 80%. Moreover, we tested recombinant proteins or peptides of specific tetraspanin domains
on their effect on the most oncogenic HPV type, HPV16, and HCMV. We found that the C-terminal
tails of CD63 and CD151 significantly inhibited infections of both HPV16 and HCMV. Although CD9
was newly identified as a key cellular factor for HPV16 infection, the recombinant CD9 C-terminal
peptide had no effect on infection. Based on the determined half-maximal inhibitory concentration
(IC50), we classified CD63 and CD151 C-terminal peptides as moderate to potent inhibitors of
HPV16 infection in HeLa and HaCaT cells, and in EA.hy926, HFF (human foreskin fibroblast) cells,
and HEC-LTT (human endothelial cell-large T antigen and telomerase) cells for HCMV, respectively.
These results indicate that HPV16 and HCMV share similar cellular requirements for their entry
into host cells and reveal the necessity of the cytoplasmic CD151 and CD63 C-termini in virus
infections. Furthermore, this highlights the suitability of these peptides for functional investigation
of tetraspanin domains and as inhibitors of pathogen infections.
Keywords: human papillomavirus; HPV16; human cytomegalovirus; tetraspanin; virus entry;
blocking peptide; IC50
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1. Introduction
Tetraspanin proteins play important roles during the life cycle of numerous viruses [1–5]. It has
been suggested that virus entry involves specific tetraspanins such as cluster of differentiation (CD)
tetraspanins CD9, CD63, CD81 and CD151, making them putative antiviral targets.
The widely expressed family of tetraspanin proteins is composed of 33 members in humans [6].
Tetraspanins localize in the plasma membrane and the membranes of intracellular compartments.
They are structurally conserved harboring four transmembrane domains, three intracellular domains as
well as a small and a large extracellular loop [7–11]. The large extracellular loop (LEL) of tetraspanins
is a flexible functional domain with a variable sequence but different tetraspanins share a conserved
structure [12–14]. Due to its ability to facilitate specific interactions, the LEL supports anchoring
of multiple proteins to one site of the membrane [9,12]. The short cytoplasmic C-terminal tail of
tetraspanins serves as a connector to cytoplasmic interaction partners [15–19]. Despite their relative
shortness of about a dozen amino acids, some tetraspanin C-termini contain functional units, such as
the C-termini of tetraspanins CD63 and CD151 that contain a tyrosine-based sorting motif essential for
their subcellular localization [16,20]. Different tetraspanin domains can simultaneously interact with
other tetraspanins or proteins from other protein families and thereby locally concentrate molecules in
a functional network, the tetraspanin-enriched microdomains (TEMs or TERMs) [21,22]. The ability to
form TEMs and co-integrate interaction partners such as growth factor receptors, adhesion molecules,
and proteases into these assemblies enables local concentration of factors required for virus entry [5].
Human papillomaviruses (HPV) are small, nonenveloped DNA viruses infecting the skin and
mucosa. Depending on the HPV type, infection causes either the formation of benign warts or
malignant tumors. The high-risk HPV types are responsible for severe human cancers, including almost
all cases of cervical cancer and numerous anogenital, head, and neck tumors [23,24]. High-risk HPV
type 16 (HPV16) is most studied as it displays the highest oncogenic potential [25,26]. This HPV type
requires a distinct set of receptors and accessory proteins such as tetraspanins [27–29], laminin-binding
integrins [28,30–32], and growth factor receptors (GFRs) [33], for its uptake into the cell (reviewed
in [34–36]). Tetraspanin CD151 is able to interact with these HPV16 entry factors [9,37] and mediates
virus uptake via a clathrin-, caveolin- and dynamin-independent endocytic pathway [28,38,39].
Moreover, mutational analyses uncovered CD151 domains that are critical for endocytic uptake of
HPVs, like the integrin-interacting domain of the LEL or the cytoplasmic C-terminus [28,39]. Following
endocytosis, virions are trafficked via endosomal structures. This post-endocytic trafficking requires
tetraspanin CD63 [40]. Here again, the functionality of its C-terminus is required for HPV16 infection
as it is essential for the interaction with the adaptor protein syntenin-1 [16,40]. CD63/syntenin-1
complex formation ensures HPV trafficking to multivesicular bodies. This step is vital for viral capsid
disassembly, and mediates the delivery of the viral genome to the host cell nucleus [40]. Additionally,
HPV infection induces clustering of CD81 on T-cell membranes leading to the formation of large cluster
networks required for viral uptake [29]. Therefore, in addition to CD151 and CD63, other tetraspanins
might be involved in HPV infection as it has been shown for other viruses like HCMV [3–5,41].
Human cytomegalovirus (HCMV), an enveloped DNA virus and member of the herpesviridae
family, can cause life-threatening disease in immunocompromised individuals and is among the
leading causes of infection-related birth defects [42,43]. At present, there is no vaccine that provides
sufficient protection from HCMV infection, therefore the need to identify new antiviral drug targets
remains. For successful entry into certain cell types, such as epithelial and endothelial cells, HCMV
requires several cellular factors such as tetraspanin proteins CD9, CD63, CD81, and CD151 [4,41],
integrins [44,45], growth factor receptors (epidermal GFR and platelet-derived GFR alpha) as well as
neuropilin-2 which have been separately investigated [46–48].
In this study, the general requirements of the tetraspanins CD9, CD63, CD81, and CD151 in
infections by the most oncogenic HPV type, HPV16, were tested as previously investigated for HCMV.
Although future research is required to identify the precise role of tetraspanins CD9 and CD81, our
study is the first to define them as novel players in HPV16 infection. Furthermore, we analyzed the
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involvement of specific tetraspanin domains, the LEL and the C-terminus, in HPV and HCMV infection
by using recombinant peptides or proteins comprising these domains of CD9, CD63, CD81 and CD151
tetraspanins. We demonstrate that C-terminal peptides of CD63 and CD151 exhibit a moderate to
potent inhibitory effect on HPV16 and HCMV infections. These findings suggest that the function of
the C-terminus of CD151 and CD63 but not of CD9 is of particular importance for virus entry and
infection. In conclusion, our results highlight the C-terminal tails of CD63 and CD151 as effective
HPV16 and HCMV entry inhibitors. Moreover, we find peptides of functional tetraspanin domains as
useful tools to investigate the role of tetraspanins and their domains in virus infections.
2. Results
2.1. Cluster of Differentiation (CD) Tetraspanins CD9, CD63, CD81 and CD151 Are Required for Human
Papillomavirus Type 16 (HPV16) Infection.
Tetraspanin assemblies play an important role in virus entry [5]. It has been shown that CD9, CD81
and CD151 were downregulated during HCMV entry and that cellular depletion of CD9, CD63 and
CD151 reduced HCMV infection [4,41]. Oncogenic HPV types utilize TEMs with tetraspanin CD151 as
a key player during endocytosis [28,38]. Moreover, tetraspanin CD63 is crucial for post-endocytic virus
trafficking, ensuring delivery of the viral DNA to the host cell nucleus [40]. In addition, we have shown
earlier that neutralizing antibodies specific for CD63 and CD151 reduced infectivity in HEK293TT
cell line [27–29]. The importance of tetraspanins CD9 and CD81 for HPV infection has not yet been
revealed. To test whether additional tetraspanins are involved in HPV16 infection, we applied a
pseudovirus (PsV) infection assay, depleting either CD9 or CD81. siRNAs targeting CD151 and CD63
served as a control for impaired infection. HeLa cells were incubated with specific tetraspanin siRNAs
as indicated for 48 h before infection with HPV16 PsVs. All tested tetraspanin siRNAs induced a
significant reduction in HPV16 infection rates (Figure 1). Cellular depletion of CD81 induced a weak
infection rate inhibition of 25 to 30%. Knockdown of CD63 displayed a reduction of infection by more
than 50% and CD9 knockdown resulted in a strong inhibition of about 90%, which was comparable to
results obtained by CD151 siRNAs. Since the knockdown efficiency of tetraspanin CD63 is stronger
than the assessed infectivity after its depletion, it is likely that another tetraspanin might overtake the
role of CD63. Together, these results emphasize the role of different tetraspanins in HPV infection and
uncover the importance of CD9 for infection of HeLa cells.
Figure 1. Tetraspanins CD9, CD63, CD81, and CD151 are required for HPV16 infection. HeLa cells
were treated with control, tetraspanin CD9, CD63, CD81 or CD151 specific siRNAs (#1 or #2) for
48 h, then infected with HPV16 PsVs for 24 h. Upper panels show siRNA knockdown efficiency
(β-actin served as loading control). Graphs presented on the lower panels show relative infection rates
assessed by measuring luciferase activity since HPV16 PsVs harbor a luciferase expression plasmid.
Data sets are shown as mean ± standard error of the mean (SEM) and were normalized to the mean
of control siRNA treated cells (set to 100%). Asterisks indicate significant differences to the control
(p < 0.05).
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2.2. Peptides Comprising the Large Extracellular Loop of Tetraspanins Interfere with HPV16 Infection.
The large extracellular loop of tetraspanin proteins is a variable functional region. It mediates
tetraspanin interactions with other tetraspanin molecules or interacting partner proteins [12–14,29,49],
thereby contributing to the formation of functional tetraspanin-enriched microdomains. Recombinant
proteins comprising LELs of tetraspanins involved in HPV and HCMV entry might inhibit infection
by competitively binding PsVs or tetraspanin interaction partners. To this end, LEL-GST (glutathione
S-transferase) fusion proteins of tetraspanins CD9, CD63, CD81 or CD151 were produced and purified
as previously demonstrated [50]. HeLa and HaCaT cells were incubated with these recombinant LELs
for 1 h and subsequently infected with HPV16 PsVs. The LELs of CD63, CD81 and CD151 induced a
minor, but significant reduction of HPV infection rates in HeLa and HaCaT cells at 24 h post infection
(h.p.i.) (Figure 2A). To test whether the LELs affect HCMV infection, EA.hy926 cells were incubated
with the recombinant proteins and subsequently infected with HCMV strain TB40/E. At 24 h.p.i.,
the cells were fixed and the fraction of infected cells expressing viral immediate early antigen (IE-Ag)
was determined via immunofluorescence. None of the tested tetraspanin peptides affected HCMV
infection (Figure 2B). These results suggest that proteins comprising the LELs of CD9, CD63, CD81
and CD151 have a weak inhibitory effect on HPV infection and no effect on HCMV infection.
Figure 2. Peptides comprising the large extracellular loop of tetraspanins interfere with HPV16
infection. (A) HeLa and HaCaT cells were incubated with 500 nM glutathione S-transferase (GST)
negative control protein or GST fusion proteins comprising the large extracellular loop of tetraspanin
CD9, CD63, CD81 or CD151 for 3 h. Cells were infected with HPV16 PsVs and relative infection rate
was assessed by measuring luciferase activity 24 h post infection (h.p.i.). (B) EA.hy926 cells were
incubated with 500 nM GST negative control protein or GST fusion proteins of the large extracellular
loop of tetraspanin CD9, CD63, CD81, or CD151 for 2 h. Cells were infected with HCMV strain TB40/E
and analyzed via immunofluorescence. The fraction of infected cells was calculated by dividing the
number of immediate early antigen (IE-Ag) positive cells by the number of DAPI positive nuclei 24 h.p.i.
The data is shown as mean ± SEM and was normalized to the mean of control peptide (GST) treated
cells (set to 100%). Asterisks indicate significant differences compared to control (p < 0.05).
2.3. Blocking Peptides of the Cytoplasmic C-Terminal Tail of Tetraspanins Inhibit HPV16 Infection.
The cytoplasmic C-terminal domain of tetraspanins is a functional region required for interaction
with cytoplasmic partner proteins [15–19]. The C-terminus of CD63 facilitates complex formation
between CD63 and its direct interaction partner syntenin-1 [16], which is required for post-endocytic
trafficking of HPV [40]. Moreover, HPV infection involves the C-terminus of CD151 [28],
which affects integrin functions and links CD151 to intracellular pathways [51–54]. Therefore, we used
cytopermeable peptides comprising the C-terminal region sequence as inhibitors of tetraspanin
functions. These peptides have been shown to block some tetraspanin-dependent functions having
the same functional effect than that of siRNA silencing [18]. In that sense, HeLa and HaCaT cells
were incubated with a control peptide comprising the scrambled combination of the ten amino acids
of CD81 C-terminus (Cont.), as well as peptides containing the C-terminal sequence of tetraspanins
CD9, CD63, CD81 and CD151, or a pool of these peptides and subsequently exposed to HPV16 PsVs.
The C-terminal peptides of tetraspanins CD63 and CD151 significantly reduced HPV infection rates in
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HeLa cells 24 h.p.i. In HaCaT cells, the C-terminal peptides of tetraspanin CD63, CD81 and CD151 as
well as the pool of all tested peptides significantly decreased HPV infection rates 24 h.p.i. (Figure 3A).
Although the recombinant peptides used are able to enter the cell [18], we applied the protein
delivery reagent PULSin to test whether the inhibitory effect of C-terminal peptides could be enhanced
by an increased cytoplasmic delivery of the peptides. HeLa and HaCaT cells were treated with peptides
pre-incubated with PULSin for 1 h before exposure to HPV16 PsVs. Indeed, the addition of the PULSin
reagent increased the inhibitory effect of HPV infection rates. In HeLa cells, C-terminal CD63, CD81
and CD151 peptides as well as the peptide pool significantly reduced HPV infection rates, whereas in
HaCaT cells all tested C-terminal peptides induced a significant reduction of the HPV infection rate
(Figure 3B).
In summary, the C-terminal peptides of tetraspanins CD63 and CD151 showed the strongest
effects on infection rates.
Figure 3. Blocking peptides of the cytoplasmic C-terminal tail of tetraspanins inhibit HPV16 infection.
(A) HeLa and HaCaT cells were incubated with 2 µM cytopermeable control peptide (scrambled amino
acid sequence of CD81; Contr.) or peptides comprising the cytoplasmic C-terminal tail of tetraspanin
CD9, CD63, CD81, CD151, or a pool of the CD9, CD63, CD81 and CD151 peptides (Pool) using 0.5 µM
of each peptide for 1 h. Next, the cells were infected with HPV16 PsVs and relative infection rate was
assessed by measuring luciferase activity 24 h.p.i. (B) HeLa and HaCaT cells were treated as in A but
the PULSin transfection reagent was present for 1 h to increase cytoplasmic delivery of the peptides.
Next, the cells were infected with HPV16 PsVs and relative infection rate was assessed by measuring
luciferase activity 24 h.p.i. The data is shown as mean ± standard error of the mean (SEM) and was
normalized to the mean of control peptide treated cells (set to 100%). Asterisks indicate significant
differences compared to control (p < 0.05).
Next, the half-maximal inhibitory concentration (IC50) of the most effective peptides, CD63 and
CD151, was determined. To exclude the cellular toxicity or other side effects of PULSin, the IC50 was
performed without any enhancers of transfection. The IC50 categorizes inhibitors into three classes:
potent (IC50 < 1 µM), moderate (1 µM < IC50 < 10 µM), or weak (IC50 > 10 µM) inhibitors [55–57].
The dose-response curves and calculated IC50 of the C-terminal CD63 and CD151 peptides in HPV
infection as well as the assessed 95% confidence interval (95% CI) are shown in Figure 4.
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Figure 4. Dose-response curves (A) and IC50 with 95% CI values (B) of C-terminal peptides of CD63
and CD151 in HPV16 infection. Cells were incubated with C-terminal peptides at final concentrations
ranging from 1 to 30,000 nM for 1 h. Afterwards, the cells were infected with HPV16 PsVs. Pseudovirus
infection assays were performed 24 h after PsVs addition. The data is shown as mean ± SEM.
2.4. Blocking Peptides of the Cytoplasmic C-Terminal Tail of Tetraspanins Inhibit Human Cytomegalovirus
(HCMV) Infection.
To examine the inhibitory effect of the blocking peptides against the C-terminal tails of tetraspanins
in a second viral infection model, EA.hy926, HEC-LTT (human endothelial cell-large T antigen and
telomerase) and HFF (human foreskin fibroblast) cells were incubated with blocking peptides of the
C-terminal tail of tetraspanins CD9, CD63, CD81, and CD151 or the control peptide and then exposed
to the HCMV strain TB40/E. Peptides comprising the C-terminal CD9 and CD81 peptide had only
minor effects on HCMV infection. However CD81 peptide significantly increased HCMV infection
in EAhy926 cells, which might be a cell line specific effect. The peptide comprising the cytoplasmic
C-terminal tail of CD151 significantly reduced HCMV infection rates in EA.hy926 and HEC-LTT cells,
while the peptide of the cytoplasmic C-terminal tail of CD63 significantly decreased HCMV infection
rates in all cell lines tested (Figure 5).
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Figure 5. Blocking peptides of the cytoplasmic C-terminal tail of tetraspanins inhibit HCMV infection.
EA.hy926, HEC-LTTs or HFF cells were incubated with 2 µM scrambled control peptide (Contr.)
or peptides with the C-terminal tail of CD9, CD63, CD151 for 2 h at 37 ◦C. Afterwards, the cells
were infected with the HCMV strain TB40/E and 24 h.p.i. fixed with 80% acetone. The fraction of
infected cells, IE-Ag positive, was determined by immunofluorescence. The data is shown as mean
± SEM and was normalized to the mean of control peptide treated cells (set to 100%). Asterisks
indicate significant differences compared to control (p < 0.05). Graphs represent data collected from
two independent experiments.
As found in HPV infection inhibition assays, peptides harboring the sequence of the C-terminus
of CD63 and CD151 displayed the strongest effect. Based on these findings, the dose-response curves
and IC50 of CD63 and CD151 in HCMV infection were determined as shown in Figure 6.
Figure 6. Dose-response curves (A) and IC50 with 95% CI values (B) of C-terminal peptides of CD63
and CD151 in HCMV infection. C-terminal peptides were used at final concentrations ranging from
30 to 4000 nM. The cells were incubated with peptide for 2 h, infected with TB40/E virus and incubated
for 2 h at 37 ◦C. The fraction of IE-Ag positive cells was analyzed by immunofluorescence staining.
The data is shown as mean ± SEM.
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2.5. C-Terminal Peptides of CD63 and CD151 Inhibit HPV16 Entry.
During HPV entry, the disassembly of the viral capsid is required for the delivery of the viral genome
into the nucleus. CD63- and CD151-depleted cells show significantly decreased capsid disassembly [28,40].
To test whether C-terminal CD63 and CD151 peptides affect HPV capsid disassembly, we used the
disassembly specific L1 antibody (L1–7) recognizing an epitope of the HPV major capsid protein L1
that is only accessible post internalization and capsid disassembly [27,58], as well as the polyclonal L1
antibody K75 detecting all bound and internalized viral particles [27,59,60] as a control for the total
amount of viral particles. HaCaT cells were transfected with peptides, incubated with HPV16 PsVs for 7 h
and analyzed via immunofluorescence. C-terminal CD63 peptide-treated cells showed the fluorescently
labeled peptides throughout the cytoplasm, matching the cellular location of CD63 cytoplasmic interaction
partner syntenin-1 [16,40]. In contrast, fluorescently labeled C-terminal CD151 peptides were observed in
proximity to the plasma membrane, were L1 staining by polyclonal K75 antibody was mainly detected,
suggesting that virus endocytosis was blocked by the CD151 peptides. Control peptide-transfected
cells readily displayed L1–7 staining, as well as K75 staining. In C-terminal CD63- and CD151-peptide
transfected cells L1–7 staining was significantly decreased compared to the control, whereas K75 staining
was readily detectable (Figure 7). These results are in line with the indicated competitive inhibitor potency
of C-terminal CD63 and CD151 peptides (Figure 3). Our results suggest that the inhibitory effect of
C-terminal CD63 and CD151 peptides occurs prior to HPV capsid disassembly conforming to the role of
CD63 and CD151 during HPV entry [28,40].
Figure 7. C-terminal peptides of CD63 and CD151 inhibit HPV16 entry. HaCaT cells were transfected
with 2 µM of control peptide or peptides comprising the cytoplasmic C-terminal tail of tetraspanin CD63
or CD151, mixed with PULSin transfection reagent 1 h prior addition to the cells. Afterwards, the cells
were incubated with HPV16 PsVs for 7 h and stained by immunofluorescence. (A) Representative
pictures of immunofluorescence with HPV16 L1 monoclonal antibody L1-7 (green), polyclonal antibody
K75 (blue), specified peptide (red) and Hoechst for DNA staining (white). L1-7 recognizes the HPV16
L1-7 epitope accessible after HPV internalization and capsid disassembly. K75 recognizes all bound
and internalized HPV particles. (B) Quantification of relative L1-7 per DNA pixels. Data is shown as
mean ± SEM and was normalized to the mean of control peptide (Cont.) transfected cells (set to 100%).
Analysis was performed on 20 images per group using ImageJ software. Asterisks indicate significant
differences compared to control (p < 0.05).
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3. Discussion
A multitude of viruses require tetraspanin proteins for infection making tetraspanins compelling
antiviral targets. In this study we compared the importance of tetraspanins CD9, CD63, CD81 and
CD151 in infections by human papilloma- and cytomegalovirus and investigated whether peptides of
functional tetraspanin domains could be used as inhibitors of HPV and HCMV infection.
Until now, the role of tetraspanins CD9 and CD81 in HPV infection remains poorly defined.
Our experiments with siRNA-mediated knockdown of CD9 and CD81 in HeLa cells highlighted the
importance of both tetraspanins in HPV16-mediated infection. CD9-targeting siRNAs reduced the
HPV infection rate to an extent similar to the siRNA directed against CD151, whose crucial role in
HPV infection was stated earlier [27,28,38]. A significant reduction of infection by nearly 90% after
CD9 depletion makes this tetraspanin an interesting target of investigation for future HPV research.
In comparison, CD81 depletion reduced HPV16 infection by approximately 30%. This was comparable
to a previous study showing that the inhibitory effect of antibodies against CD81 was weaker than that
of antibodies against CD63 and CD151 in HPV16 infection [27]. These results indicate that different
tetraspanins have individual potencies in benefitting HPV infection. CD81 seems to play a minor role
in HPV infection, whereas CD9 is likely to be a major player.
LELs are functional tetraspanin domains that have previously been shown to be involved in
viral infection [14,29,61,62]. However, our data shows that soluble proteins comprising the LELs of
CD9, CD63, CD81 and CD151 inhibit HPV infection to a significant but minor extent and pose no
effect on HCMV infection. These findings are in strong contrast to the results reported for infection
with human immunodeficiency virus (HIV), in which recombinant CD9, CD63, CD81 and CD151
LELs were identified as potent inhibitors [61]. Moreover, it was shown that recombinant CD81 LEL
proteins are able to sufficiently bind Hepatitis C virus by interacting with its major virus envelope
protein E2 [63], implying that LEL proteins are capable of competitively interacting with virions.
Our results suggest that the LEL proteins do not capture HPV or HCMV virions nor interfere with
other tetraspanin interactions involved in HPV and HCMV infection. Therefore, the antiviral potency
of LEL proteins might be virus specific and requires further investigation.
More importantly, we show that cytopermeable peptides comprising the C-termini of CD63 and
CD151 had a moderate to potent inhibitory effect on HPV16 and HCMV infections in different cell
lines. Simultaneous addition of all tested tetraspanin peptides was unable to increase the effect of
the individual peptides. Interestingly, CD9-targeting siRNAs caused a significant reduction of HPV
(Figure 1) and HCMV [4] infections, whereas the C-terminal peptide had no or only a minor inhibitory
effect. This discrepancy of the consequences of cellular depletion versus treatment of cells with CD9
C-terminal peptides might imply that CD9 affects HPV and HCMV infection via a function that does
not involve C-terminal dependent cytoplasmic interactions. Therefore it is likely that CD9 benefits
HPV and HCMV infection by organization of virus entry platforms (TEMs) [5] or the modulation of
the activity or accessibility of interaction partners like proteases as it was proposed for entry of MERS
viruses [64].
Overall, concentration curves of blocking peptides against the cytoplasmic C-terminal tail of
tetraspanins CD63 and CD151 produced effective reduction in both viral infection systems and in
all tested cell models, indicating that these peptides might be useful for development of HPV and
HCMV inhibitors. This is in line with previous studies demonstrating that CD63 and CD151 are
involved in HPV and HCMV infection and that the C-terminal domains of these tetraspanins are
indispensable for their role in virus infection [4,27,28,38,40]. Moreover, the comparable effects of
siRNA and C-termini treatment suggests that these two viruses take advantage of similar cellular
pathways during infectious entry.
Mechanistically, we show that the CD63 and CD151 C-terminal peptides decreased the
disassembly of HPV16 capsids which consequently inhibited infection. We observed differences
in the cellular localization of the CD63 and CD151 peptides which might indicate the localization
of the tetraspanin interaction partners. Direct interaction of CD63 C-terminus has been previously
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reported for the cytoplasmic adaptor proteins syntenin-1 [16] and AP subunits [17]. However, little is
known about direct interactions facilitated by the CD151 C-terminus [12]. Moreover, distribution of the
HPV16 capsid protein L1 indicates that C-terminal CD151 peptide is able to block virus endocytosis as
the capsid protein was mainly detected in the cell periphery. On the other hand, cells treated with the
CD63 peptide displayed evenly distributed capsid staining throughout the cytoplasm accompanied by
reduced capsid disassembly suggesting inhibited intracellular trafficking and endosomal maturation.
These findings are in line with the effect described for cellular depletion of these tetraspanins [28].
Our data suggests that the tetraspanin C-terminal peptides can specifically block the function of
the corresponding tetraspanin domains, making them suitable reagents for investigating the role of
tetraspanins in their diverse cellular functions. Furthermore, with assessed IC50 values lower than
1 µM for HCMV and lower than 10 µM for HPV, the C-terminal peptides of CD63 and CD151 can be
classified as potent and moderate antiviral agents for HCMV and HPV infection, respectively, making
them an interesting tool for entry prevention of other viruses.
4. Materials and Methods
4.1. Cell Lines and Pseudoviruses
The human cervical carcinoma cell line HeLa was purchased from the German Resource Centre
for Biological Material (DSMZ, Braunschweig, Germany). The human nonvirally immortalized
keratinocyte cell line HaCaT was purchased from Cell Lines Services (CLS, Eppelheim, Germany).
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM + GlutaMAX, Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS), 1% minimum
essential medium nonessential amino acids (MEM nonessential amino acids, Thermo Fisher Scientific,
Waltham, MA, USA) and the antibiotic ciprofloxacin.
Human foreskin fibroblast (HFF), primary cells isolated from human tissue, were grown in
MEM + GlutaMAX (Life Technologies, Darmstadt, Germany) supplemented with 5% FCS, basic
fibroblast growth factor (0.5 ng/mL) and the antibiotic gentamicin (100 µg/mL).
EA.hy926 cells (ATCC CRL-2922), a hybrid cell line previously generated by fusion of human
umbilical vein endothelial cells (HUVEC) and A-549 cells was purchased from LGC Standards
(Wesel, Germany). Cells were grown in DMEM + GlutaMAX (Life Technologies), 10% FCS and
antibiotic gentamicin [65].
Human endothelial cell-large T antigen and telomerase (HEC-LTT), a conditionally immortalized
cell line generated from human umbilical vein endothelial cells (HUVEC) by introducing
doxycycline-inducible gene expression cassettes for the simian virus 40 (SV40) large T antigen and
the human telomerase catalytic subunit was kindly provided by Dagmar Wirth (Helmholtz Centre for
Infection Research, Braunschweig). Cells were grown in EGM-BulletKit (CC-3124) (Lonza Sales Ltd.,
Basel, Switzerland): EBM (endothelial basal medium), bovine brain extract with heparin, human
endothelial growth factor, hydrocortisone, ascorbic acid, GA-1000 (gentamicin, amphotericin B) and 2%
FCS. For passaging the culture medium was supplemented with doxycycline (2 µg/mL) immediately
before addition to the cells [65].
HPV16 pseudoviruses were prepared as described earlier [66]. HCMV strain TB40/E was
originally isolated from a throat wash specimen obtained from a bone marrow transplant patient and
subsequently propagated in HUVECs [67].
4.2. CD9, CD63, CD81 and CD151 siRNA Knockdown
CD9#1 (Hs_CD9_1), CD9#2 (Hs_CD9_7), CD81#1 (Hs_CD81_11), and CD81#2 (Hs_CD81_6) were
purchased from Qiagen (Hilden, Germany). CD63#1 and CD151#1 were purchased from Sigma-Aldrich
(St. Louis, MO, USA), and have been described previously [28,40]. Sequences are available upon request.
Non-silencing control siRNA (AllStars Neg. Control siRNA, Qiagen) was used as control. HeLa cells were
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transfected with 30 nM siRNA using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) for 48 h
according to manufacturer’s instructions. Knockdown efficiency was quantified by Western blotting.
4.3. Antibodies
Mouse monoclonal CD9 and CD81 antibodies were purchased from Acris (Rockville, MD, USA)
and Santa Cruz (Dallas, TX, USA), respectively. CD63 and CD151 antibodies were described
earlier [28,40]. The HPV L1-specific antibodies mouse monoclonal antibody L1-7 and rabbit polyclonal
antibody K75 were described previously [27,58,68]. Anti-IE-Ag (clone E13), mouse monoclonal
antibody targeted against viral immediate early antigens 1 and 2 was purchased from Argene
(Verniolle, France). Secondary, Cy3-conjugated goat polyclonal anti-mouse-Ig F(ab’)2 antibody was
from Jackson ImmunoResearch (Baltimore, MD, USA).
4.4. LEL Proteins and C-Terminal Peptides
Recombinant fusion proteins mimicking the large extracellular loop of tetraspanins CD9, CD63,
CD81 and CD151 as well as the glutathione S-transferase (GST) fusion partner were produced in
E. coli and purified as previously described [50]. Peptides of the cytoplasmic C-terminal tail of
tetraspanins CD9, CD63, and CD151 are tetramethylrhodamine (TAMRA) N-terminal–labeled peptides
with the sequences RRRRRRRCCAIRRNREMV (CD9), RRRRRRRCCLVKSIRSGYEVM (CD63),
RRRRRRRCLYRSLKLEHY (CD151) and were purchased from LifeTein (South Plainfield, NJ, USA)
or DgPeptides (Hangzhou, Zhejiang, China). Peptides of the cytoplasmic C-terminal tail of CD81 as
well as a CD81 scrambled negative control peptide have been described earlier [18,69].
4.5. HPV Inhibition Assay
HeLa and HaCaT cells were grown in 24- or 48-well plates and incubated with tetraspanin
specific siRNAs, LELs or C-terminal peptides. Cells were infected with 100 luciferase vector positive
HPV16 pseudoviruses per cell for 24 h. Luciferase expression control and HPV pseudovirus infection
assays were performed as described previously [28,70]. Luciferase counts were normalized to lactate
dehydrogenase (LDH) to take the cell viability into account.
To determine the effect of recombinant LEL proteins, HeLa and HaCaT cells were incubated with
specified LELs in medium without supplements for 3 h before exposure to HPV16 PsVs. To determine
the impact of C-terminal tetraspanin peptides two approaches were used:
(1) The cells were incubated with C-terminal tetraspanin peptide in medium without supplements
for 1 h and subsequently infected with PsVs.
(2) The cells were transfected with a mixture of C-terminal tetraspanin peptide and a PULSin
(Polyplus-transfection, Illkirch, France) preincubated for 1 h in medium without supplements before
PsVs addition and were further cultured in medium with FCS. PULSin was used according to
manufacturer’s instructions.
4.6. HCMV Inhibition Assay
To determine the effect of proteins comprising LELs or C-terminal tails, the cells were incubated
with specified reagents for 2 h before infection with HCMV strain TB40/E. The fraction of infected
cells (IE-Ag positive cells) was detected with immunofluorescence staining applying primary
antibody against immediate early antigen (IE-Ag) and Cy3-conjugated secondary antibody as
described before [4]. Nuclei were counterstained with DAPI. A Zeiss Axio Observer D1 microscope
(Zeiss, Jena, Germany) was used for visualization of fluorescence. Strain TB40/E was used at a
multiplicity of infection (MOI) of 0.5 to 1.
Int. J. Mol. Sci. 2018, 19, 3007 12 of 17
4.7. IC50 Determination
To determine the IC50 (concentration necessary to achieve the half-maximal inhibition) for HPV,
HeLa and HaCaT cells were incubated with C-terminal peptides at final concentrations ranging from
1 to 30,000 nM for 1 h in medium without supplements. Afterwards, the cells were infected with
about 100 luciferase vector positive HPV16 pseudoviruses per cell. Pseudovirus infection assays were
performed 24 h after PsVs addition as described above. Luciferase counts were normalized to lactate
dehydrogenase (LDH) to take the cell viability into account. Analysis was performed using GraphPad
Prism 5 Software, Inc. (San Diego, CA, USA) (www.graphpad.com). The data were normalized to the
mean of the smallest tested concentration that was set to 100%.
To determine the IC50 for HCMV, C-terminal peptides were used at final concentrations ranging
from 30 to 4000 nM. The cells were incubated with peptide for 2 h. Then, the cells were infected
with TB40/E virus and incubated for 2 h at 37 ◦C. Afterwards, the medium containing the virus was
exchanged by fresh medium supplemented with FCS. The fraction of infected cells, (IE-Ag positive cells)
was then analyzed by immunofluorescence staining applying primary antibody for immediate early
antigen (IE-Ag) and Cy3-conjugated secondary antibody. Analysis was performed using GraphPad
Prism 5 Software, Inc. The data were normalized to the mean of the smallest tested concentration that
was set to 100%.
4.8. Immunofluorescence
HeLa or HaCaT cells were grown on cover slips. After transfection and/or infection, cells
were fixed and permeabilized in methanol. Afterwards, cells were incubated with primary antibody
and species-specific Alexa-conjugated secondary antibodies (Invitrogen). Nuclear DNA staining was
achieved by incubation with Hoechst 33,342 (Sigma-Aldrich). Cover slips were mounted on microscope
slides using Dako Fluorescent Mounting Medium (Dako, Carpinteria, CA, USA). Images were acquired
using Zeiss Axiovert 200 M microscope fitted with the Plan-Apochromat 100×/1.4 Oil objective and
Axiovision deconvolution software (Carl Zeiss, Jena, Germany).
For determination of disassembled HPV16 PsVs (L1–7 epitope detection assay) HaCaT cells
were grown on cover slips, transfected with C-terminal tetraspanin peptide for 1 h and infected with
100 HPV16 pseudovirus particles per cell for 7 h. Cells were fixed and permeabilized in methanol
and stained with monoclonal antibody L1–7 as described in Spoden et al. 2008 [27]. Cover slips were
mounted and images of 20 randomly selected cell islands per group were acquired as described above.
4.9. Statistics
If not stated otherwise, the experiments were repeated at least three times. Statistical analysis
of all analyzable data points was assessed with two-tailed, unpaired t-tests using GraphPad Prism
software and Microsoft Office Excel 2016. p-values smaller then 0.05 (p < 0.05) were considered as
significant differences between groups.
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Abbreviations
CD cluster of differentiation
CI confidence interval
DAPI 4′,6-Diamidin-2-phenylindol
FCS fetal calf serum
GFR growth factor receptor
GST glutathion-S-transferase
HCMV human cytomegalovirus
HEC-LTT human endothelial cell-large T antigen and telomerase
HFF human foreskin fibroblast
h.p.i. hours post infection
HPV human papillomavirus
IC50 half-maximal inhibitory concentration
IE-Ag immediate early antigen
LDH lactate dehydrogenase
LEL large extracellular loop
MOI multiplicity of infection
PsV pseudovirus
SEM standard error of the mean
TEM tetraspanin-enriched microdomain
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